Estimating the burden of RSV infection in older adults (215292)
Research type
Research Study
Full title
A cross-sectional, multi-centre, epidemiological study to estimate the burden of respiratory syncytial virus (RSV) infection in adults aged ≥ 60 years, presenting at general practitioners (GPs) and outpatient clinics/ outpatient hospitals with acute respiratory infection (ARI) in Europe.
IRAS ID
300048
Contact name
Susannah Eyre
Contact email
Sponsor organisation
GSK Vaccines
Duration of Study in the UK
1 years, 8 months, 30 days
Research summary
Respiratory Syncytial Virus (RSV) is a virus that can cause respiratory illnesses. Severe RSV illness can result in pneumonia (lung infection) and can cause respiratory failure or death.
Older adults have a higher risk of severe RSV illness than younger adults. This is due to the natural weakening of the body’s defence (immune) system with age.
This is an ‘epidemiological’ study which will be conducted in Europe and follow adults aged 60 years and above with respiratory illness during two consecutive RSV seasons (1500 adults in first season from 1 October 2021 to 30 April 2022, 1500 adults in the second season from 1 October 2022 to 30 April 2023). This GSK study will help us to estimate the burden of RSV infection in older adults. We will also study how RSV affects quality of life and health care services used by the people who will participate in this study.
REC name
South West - Frenchay Research Ethics Committee
REC reference
21/SW/0084
Date of REC Opinion
11 Aug 2021
REC opinion
Further Information Favourable Opinion